News
Si avvisano tutti gli studenti interessati che le lezioni del corso di Analisi Chimico Farmaceutica e Tossicologica I (M-Z) per l’anno accademico 2024/2025 avranno inizio martedì 1 ottobre 2024 e proseguiranno con il seguente orario:
- lunedì 15:00 - 18:00, edificio CU019, Aula A Raffaele Giuliano;
- martedì 11:00 - 13:00, edificio CU019, Aula Magna Fulvio Cacace.
Receiving hours
Concordato via email. Il docente riceve gli studenti esclusivamente in presenza presso la stanza 208, piano 2, edificio CU019.
Curriculum
Personal Information
Surname and Name: La Regina Giuseppe
Office address and contacts: Dipartimento di Chimica e Tecnologie del Farmaco, Sapienza Università di Roma, Piazzale Aldo Moro 5, 00185, Rome, Italy.
Office: building CU019, floor 2, room 208, Tel +39 0649913893, Fax +39 0649913789.
Research laboratory: building CU020, floor 1, room 5A, Tel +39 0649913404, Fax +39 0649913993.
Teaching laboratory: building CU019, floor 1, room 1.
E-mail: giuseppe.laregina@uniroma1.it
Certified email: giuseppe.laregina@postecert.it
Website: https://corsidilaurea.uniroma1.it/it/users/giuseppelareginauniroma1it
Current Position
Since September 2019: Associate Professor in Medicinal Chemistry, Dipartimento di Chimica e Tecnologie del Farmaco, Sapienza Università di Roma.
Main Scientific Interests
Design, synthesis and development of anti-infective (human immunodeficiency virus, rhinovirus, hepatitis C virus, dengue virus, coronavirus, norovirus, zika virus, Mycobacterium tuberculosis and Candida albicans), anti-cancer (tubulin and microtubules, Wnt/beta-catenin signalling, histone demethylases, matrix metalloproteinases, B-cell lymphoma-2, carbonic anhydrase, indoleamine 2,3-dioxygenase 1, murine double minute 2 and 4 proteins, Na+/H+ exchanger 3 regulating factor 1, growth factor receptor bound protein 2, lactate dehydrogenase, PDZ domains, apoptosis and ferroptosis) and central nervous system active (monoamine oxidases, endocannabinoid system, glycogen synthase kinase 3 beta) agents; microwave-assisted synthesis and fully automated chromatography purification of heterocyclic compounds.
Work Experience
November 2008 – September 2020: Assistant Professor in Medicinal Chemistry, Dipartimento di Chimica e Tecnologie del Farmaco, Sapienza Università di Roma.
March 2007 - November 2008: Design, synthesis and development of new inhibitors of tubulinpolymerization as anticancer agents, Dipartimento di Chimica e Tecnologie del Farmaco, SapienzaUniversità di Roma (3-year grant financed by AIRC/FIRC, Milan, Italy).
April 2005 - March 2007: Molecular modelling studies to design new inhibitors of tubulin polymerization asanticancer agents, postdoctoral position, Welsh School of Pharmacy, Cardiff University, UK, (2-year grantfinanced by Institut Pasteur - Cenci Bolognetti Foundation, Rome, Italy).
November 2001 - October 2004: PhD course in Medicinal Chemistry, Dipartimento di Chimica e Tecnologiedel Farmaco, Sapienza Università di Roma.
Education
Italian Level 2 Master in Drug Design and Development: May 2007, Università degli Studi di Pavia, Pavia,Italy.
PhD in Medicinal Chemistry: March 2005, Dipartimento di Chimica e Tecnologie del Farmaco, SapienzaUniversità di Roma.
Graduation in Pharmacy: July 2001, full marks, Faculty of Pharmacy, Sapienza Università di Roma.
Scientific Publications
Co-Author of more than 100 scientific papers and 5 patents (number of documents: 114; h-index: 37; overall citations: 4334; https://www.scopus.com/authid/detail.uri?authorId=6602306518; Scopus, May 2025).
Congresses, Meetings and Workshops
15 oral and more than 100 poster communications in national and international meetings; member ofscientific and organizing committees in national and international meetings.
Awards and Qualifications
2018: Publons Peer Review Award 2017
2017: National Scientific Qualification for Full Professor Position in Medicinal Chemistry (03/D1, D.D. n. 1532/2016).
2014: National Scientific Qualification for Associate Professor Position in Medicinal Chemistry (03/D1, D.D. n. 222/2012).
2007: Farmindustria Prize for Pharmaceutical Research - Outstanding for researching activity.
Relevant Positions
Sapienza Università di Roma: President of the Degree Programme Commission in Industrial Pharmacy.
Sapienza Università di Roma: Member of scientific board of PhD Course in Molecular Design and Characterization for the Promotion of Health and Well-being: From Medicine to Food.
Istituto Pasteur Italia – Fondazione Cenci Bolognetti, Rome, Italy: member of Scientific Direction.
Teaching Activity
Dipartimento di Chimica e Tecnologie del Farmaco, Sapienza Università di Roma: a) Professor of Inorganic Drug Analysis; b) Professor of Acquisition of IT Skills and Monitoring of Prescriptions and Analysis of Drug Consumption in Hospital; c) Professor of Nutraceutical Principles; d) member of examination committee inMedicinal Chemistry courses; e) member of examination committee of graduating students in Pharmacyand Chimica e Tecnologia Farmaceutiche (Pharmaceutical Chemistry and Technology); f) member ofexamination committee of PhD students in Medicinal Chemistry (Doctor Europaeus); g) tutor of graduatingstudents in Pharmacy and Chimica e Tecnologia Farmaceutiche; h) supervisor/tutor of PhD students inMedicinal Chemistry.
Facoltà di Medicina e Chirurgia “A. Gemelli”, Rome, Italy: Professor of Quantitative Analysis of Drugs and Qualitative Analysis of Drugs.
Principal Investigator of Funded Research Projects
Finanziamenti di Ateneo 2023, Sapienza Università di Roma: Tubulin inhibitors as ferroptosis inducers incancer treatment; RG123188B4D193AE; 18 months, 60840 euro.
Bando PRIN 2022, Ministero dell'Università e della Ricerca: Targeting Wnt/beta-catenin pathway:identification and development of selective allosteric modulators of Dishevelled and Frizzled proteins as apromising approach to cancer therapy (INdWNT); 2022TPPNTK; 24 months, 203748 euro.
Finanziamenti di Ateneo 2019, Sapienza Università di Roma: Treatment of chronic myeloid leukemia byinhibition of tubulin polymerization; RM11916B5598E3C4; 18 months, 14500 euro.
Call 2019, Istituto Pasteur – Fondazione Cenci Bolognetti: Treatment of chronic myeloid leukemia byinhibition of tubulin polymerization; 24 months, 40000 euro.
Finanziamento delle attività base di ricerca 2017, Agenzia Nazionale di Valutazione del SistemaUniversitario e della Ricerca, 3000 euro.
Finanziamenti di Ateneo 2017, Sapienza Università di Roma, Hit to lead optimization of arylthioindoles andaroylindoles as modern anticancer agents, RP11715C7D1CF0D1, 18 months, 4000 euro.
Finanziamenti Ateneo 2016, Sapienza Università di Roma, Targeting colchicine binding site of tubulin byindole- and pyrrole-based anticancer agents, RG116154CF287B95, 18 months, 30000 euro.
Ricerche Universitarie 2015, Sapienza Università di Roma, New inhibitors of tubulin polymerization asanticancer agents endowed with stimulation of natural killer cell cytotoxic activity and repression ofHedgehog signalling pathway, C26A15J3BB, 18 months, 34450 euro.
Ricerche Universitarie 2014, Sapienza Università di Roma, Development of new compounds as anticancerand analgesic agents, C26A14TLFT, 18 months, 20000 euro.
Progetti Awards Ricerche Universitarie 2013, Sapienza Università di Roma, Tubulin and TRP channels astargets for new antitumor and analgesic agents, C26H135FL5, 18 months, 55000 euro.
Università degli Studi di Roma “La Sapienza”, Congressi e convegni 2013, XXII National Meeting onMedicinal Chemistry, C26C12KS92, 18 months, 3500 euro.
FIRB Futuro in Ricerca 2010, Ministero dell’Istruzione, dell’Università e della Ricerca, Mitochondrialmedicinal chemistry against cell death-resistant cancers, RBFR10ZJQT_003, 36 months, 307671 euro.